Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Alvotech announces approval of AVT 03, a biosimilar to Prolia and Xgeva (denosumab) in the European Economic Area

Written by | 7 Dec 2025

Alvotech announced that the European Commission (EC) has approved AVT 03 as a biosimilar to Prolia and Xgeva (denosumab). AV T03 is approved in two presentations: as a… read more.

CHMP positive for Stoboclo (denosumab biosimilar) intended for the treatment of osteoporosis in post menopausal women, bone loss in men and treatment of systemic glucocorticoid – Celltrion

Written by | 19 Dec 2024

On 12 December 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Stoboclo (denosumab… read more.

CHMP positive for Jubbonti a denosumab (Prolia) biosimilar – Sandoz

Written by | 26 Mar 2024

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Jubbonti, intended for the… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.